Newsletter | September 22, 2020

09.22.20 -- Tiny Antibody Component Highly Effective Against COVID-19

Industry Insights
Built To Fail: How Today’s Manufacturing Options Leave Pharma At Risk

Though pharma companies do their best to understand the environment, it can be very difficult to predict demand, and the consequences of incorrect forecasts can be very costly in a number of ways. 

New Normal In Quantative Western Blot Analysis

Normalization using total proteins present in the sample has gained significant traction and has proved to be a reliable method for normalization of western blots. This infographic illustrates why the total protein normalization (TPN) method is superior and the way to go for western blotting.

Top 5 Risks Facing Your Small Biopharma Clients Today

For small biopharma innovators, steep development costs are compounded by the fact that large molecules are becoming increasingly complex and present serious clinical or manufacturing problems.

Most Popular News
Life Science Leader Magazine

Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.